Thus, compounds targeting the same protein but exploiting different E3 ligases might represent a modality to overcome resistance, and MZ1 could be implemented alongside the other BET degraders that have shown anti-lymphoma activity [61]. The gene discussed is DNER; the disease is lymphoma.